```html

Drug Addiction – A Comprehensive Medical Guide

Overview

Drug addiction, also called substance use disorder (SUD), is a chronic, relapsing brain disease characterized by the compulsive use of psychoactive substances despite harmful consequences. It can involve legal drugs (alcohol, nicotine, prescription medications) or illegal substances (heroin, cocaine, methamphetamine).

Who it affects: Anyone can develop an addiction, but prevalence varies by age, gender, socioeconomic status, and geography.

• In the United States, ~29.5 million people (≈10.5% of the population) reported a past‑year substance use disorder in 2022 (SAMHSA, 2023).
• Men have a slightly higher risk than women (12.1% vs. 8.6%), but women progress from use to dependence more quickly, a phenomenon called “telescoping.”
• Adolescents and young adults (ages 12‑25) account for roughly 40% of all new SUD diagnoses.

Drug addiction imposes a massive public‑health burden: it accounts for an estimated 70,000 deaths annually in the U.S. and costs society $740 billion per year in health care, criminal justice, and lost productivity (CDC, 2024).

Symptoms

Symptoms can be grouped into behavioral, physical, and psychological categories. The presence of several signs over a period of months typically fulfills diagnostic criteria for SUD.

Behavioral Signs

• Craving: Persistent, intense urge to use the drug.
• Loss of control: Taking larger amounts or using for longer than intended.
• Neglected responsibilities: Declining performance at work, school, or home.
• Social withdrawal: Avoiding family/friends who do not use the drug.
• Continued use despite problems: Physical, legal, or interpersonal issues persist.
• Risky use: Engaging in dangerous activities (e.g., driving under the influence).
• Failed attempts to quit: Repeatedly trying to stop or cut down without success.

Physical Signs

• Changes in appetite or weight
• Sleep disturbances – insomnia or excessive sleeping
• Bloodshot eyes, dilated or constricted pupils
• Track marks or injection‑site scars
• Sudden deterioration of personal hygiene
• Unexplained infections (e.g., hepatitis, HIV) or frequent illnesses
• Withdrawal symptoms when the drug is not taken (e.g., tremors, sweating, nausea, anxiety)

Psychological Signs

• Mood swings, irritability, or agitation
• Depression or anxiety that fluctuates with use/withdrawal
• Paranoia or hallucinations (especially with stimulants or hallucinogens)
• Impaired decision‑making and memory problems

Causes and Risk Factors

Drug addiction results from a complex interaction of genetic, neurobiological, environmental, and psychosocial factors.

Genetic and Neurobiological Factors

• Heritability estimates range from 40‑60% for most substances (National Institute on Drug Abuse, 2021).
• Alterations in dopamine, serotonin, and opioid pathways affect reward and reinforcement.
• Early exposure can permanently change brain circuitry, making later drug seeking more likely.

Environmental and Social Factors

• Growing up in households where drug use is normalized.
• Peer pressure, especially during adolescence.
• Chronic stress, trauma, or adverse childhood experiences (ACEs).
• Poor socioeconomic status, limited educational opportunities, and community drug availability.

Psychiatric Comorbidities

• Depression, bipolar disorder, PTSD, and schizophrenia increase vulnerability.
• Self‑medication of untreated mental illness is a common pathway to SUD.

Other Risk Enhancers

• Prescription opioids or benzodiazepines for chronic pain or anxiety.
• Early onset of use (before age 15 markedly raises risk).
• Genetic polymorphisms affecting drug metabolism (e.g., CYP2D6).

Diagnosis

Diagnosis is clinical, relying on a detailed history, physical examination, and standardized criteria.

Diagnostic Criteria

The DSM‑5 (American Psychiatric Association) outlines 11 criteria; meeting ≥2 within a 12‑month period indicates a substance use disorder, graded as mild (2‑3), moderate (4‑5), or severe (≥6) (APA, 2022).

Screening Tools

• ASSIST (Alcohol, Smoking and Substance Involvement Screening Test): WHO‑endorsed, covers multiple substances.
• SATS (Substance Abuse Subtle Screening Inventory): Useful in primary care.
• CRAFFT: Designed for adolescents.

Laboratory Tests

• Urine drug screens – detect recent use of common illicit drugs.
• Blood tests – useful for suspected overdose or monitoring therapeutic drug levels (e.g., methadone).
• Hepatitis B/C, HIV serologies – indicated for injection‑drug users.
• Liver function panels – assess organ damage from alcohol or hepatotoxic substances.

Physical & Psychiatric Evaluation

Assess vital signs, withdrawal severity (e.g., Clinical Institute Withdrawal Assessment – COWS for opioids), and co‑occurring mental health conditions.

Treatment Options

Effective management combines medication, psychosocial therapies, and lifestyle interventions. Treatment is individualized, often requiring a multidisciplinary team.

Medication‑Assisted Treatment (MAT)

• Opioid Use Disorder:
  • Methadone – long‑acting opioid agonist; reduces cravings and blocks illicit opioid effects (3‑12 mg/day).
  • Buprenorphine (often combined with naloxone) – partial agonist; ceiling effect lowers overdose risk.
  • Naltrexone – opioid antagonist; oral 50 mg daily or extended‑release injectable (380 mg monthly).
• Alcohol Use Disorder:
  • Disulfiram – causes aversive reaction when alcohol is consumed.
  • Acamprosate – stabilizes brain glutamate; 666 mg three times daily.
  • Naltrexone – reduces craving; oral 50 mg daily or monthly injection.
• Nicotine Dependence:
  • Nicotine replacement therapy (patch, gum, lozenge).
  • Varenicline – partial nicotinic receptor agonist.
  • Bupropion – antidepressant that also reduces craving.

Behavioral Therapies

• Cognitive‑Behavioral Therapy (CBT): Helps patients recognize triggers, develop coping skills.
• Motivational Interviewing (MI): Enhances readiness to change.
• Contingency Management: Provides tangible rewards for drug‑free urine screens.
• 12‑Step Facilitation/Smart Recovery: Peer‑support models.
• Family Therapy: Addresses dysfunctional dynamics that sustain use.

Inpatient & Residential Programs

Intensive, structured environments are often required for severe SUD, especially when withdrawal poses medical danger. Typical stays range from 28 days to several months.

Withdrawal Management

• Opioid withdrawal: buprenorphine‑naloxone bridge, clonidine, or symptomatic treatments.
• Alcohol withdrawal: benzodiazepine taper plus thiamine to prevent delirium tremens.
• Stimulant withdrawal: primarily supportive (hydration, sleep hygiene).

Lifestyle & Complementary Strategies

• Regular aerobic exercise – improves dopamine regulation.
• Mindfulness‑based relapse prevention.
• Nutrition counseling – corrects deficiencies common in chronic users.

Living with Drug Addiction

Recovery is a lifelong process. Below are practical daily‑management tips for people in treatment or early recovery.

• Establish a Routine: Consistent sleep, meals, and activity times reduce cravings.
• Identify Triggers: Write a “high‑risk” list (people, places, stressors) and create an avoidance or coping plan.
• Build a Support Network: Attend group meetings, keep regular contact with a sponsor or therapist.
• Medication Adherence: Use pill organizers or smartphone reminders for MAT.
• Self‑Care: Practice stress‑reduction (deep‑breathing, yoga) and engage in hobbies.
• Health Monitoring: Keep scheduled labs (liver panel, viral screens) and attend follow‑up appointments.
• Legal & Financial Planning: Work with a case manager if needed to address employment, housing, or legal issues.

Prevention

Prevention strategies span individual, community, and policy levels.

Individual‑Level

• Delay initiation of any substance use; the later the first use, the lower the lifetime risk.
• Develop strong coping skills for stress and peer pressure.
• Seek treatment for mental health conditions early.

Community & School Programs

• Evidence‑based curricula such as LifeSkills Training and Project ALERT reduce experimentation.
• After‑school enrichment and mentorship programs provide alternatives to drug‑using peer groups.

Policy Measures

• Prescription Drug Monitoring Programs (PDMPs) curtail inappropriate opioid prescribing.
• Taxation and age‑restriction policies for alcohol and tobacco.
• Funding for needle‑exchange and medication‑assisted treatment expands access for high‑risk populations.

Complications

If left untreated, drug addiction can lead to acute and chronic complications affecting virtually every organ system.

Physical Health

• Cardiovascular disease – coronary artery spasm (cocaine), endocarditis (IV drugs).
• Liver disease – alcoholic cirrhosis, hepatitis C from needle sharing.
• Respiratory failure – opioid overdose, “chest infections” from smoking crack.
• Neurologic damage – seizures, stroke, cognitive impairment.
• Infectious diseases – HIV, TB, sepsis.

Mental Health

• Depression, anxiety, and suicidal ideation often worsen with continued use.
• Psychosis (e.g., methamphetamine‑induced) may become persistent.

Social & Legal Consequences

• Job loss, homelessness, and poverty.
• Legal arrests, incarceration, and loss of parental rights.
• Strained relationships leading to isolation.

When to Seek Emergency Care

---

References:

1. Substance Abuse and Mental Health Services Administration (SAMHSA). 2022 National Survey on Drug Use and Health. 2023. Link.
2. Centers for Disease Control and Prevention (CDC). Drug Overdose Deaths. 2024. Link.
3. National Institute on Drug Abuse (NIDA). Genetics of Drug Addiction. 2021. Link.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‑5). 2022.
5. Mayo Clinic. Medication‑Assisted Treatment for Opioid Use Disorder. Updated 2023. Link.
6. World Health Organization (WHO). WHO Guidelines for the Management of Substance Use Disorders. 2022.
7. Cleveland Clinic. Withdrawal Management and Detoxification. 2023. Link.

```